Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE: 300204)
Health Care · Biotechnology · CN
CN¥22.18
-11.39% today · -63.6% 1Y
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE: 300204) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.58B and employs 491 people.
Over the last twelve months the share price has lost 63.6%, trading between 18.98 and 65.36.
Tweenvest scores Staidson (Beijing) BioPharmaceuticals Co., Ltd. across four factors: quality 50/100, value 61/100, growth 0/100. Its strongest factor is value.
300204 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.58B
- Revenue (TTM)
- $29.56M
- P/E
- —
- EPS
- -0.18
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- CN¥65.36
- 52-week low
- CN¥18.98
- Avg volume (3M)
- —
- Shares outstanding
- 477.77M
- Employees
- 491
- Next earnings
- —
About Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
- ISIN
- CNE100001237
- Founded
- 2002
- Listed since
- Apr 15, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.